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ABSTRACT
The heart is the first organ to form and undergoes adaptive remodelling with age. Ventricular hypertrophy is one such
adaptation, which allows the heart to cope with an increase in cardiac demand. This adaptation is necessary as part of
natural growth from foetal life to adulthood. It may also occur in response to resistance in blood flow due to various
insults on the heart and vessels that accumulate with age. The heart can only compensate to this increase in workload
to a certain extent without losing its functional architecture, ultimately resulting in heart failure. Many genes have
been implicated in cardiac hypertrophy, however none have been shown conclusively to be responsible for pathological
cardiac hypertrophy. MicroRNAs offer an alternative mechanism for cellular regulation by altering gene expression.
Since 1993 when the function of a non-coding DNA sequence was first discovered in the model organism Caenorhabditis
elegans, many microRNAs have been implicated in having a central role in numerous physiological and pathological
cellular processes. The level of control these antisense oligonucleotides offer can often be exploited to manipulate the
expression of target genes. Moreover, altered levels of microRNAs can serve as diagnostic biomarkers, with the prospect
of diagnosing a disease process as early as during foetal life. Therefore, it is vital to ascertain and investigate the function
of microRNAs that are involved in heart development and subsequent ventricular remodelling. Here we present an
overview of the complicated network of microRNAs and their target genes that have previously been implicated in
cardiogenesis and hypertrophy. It is interesting to note that microRNAs in both of these growth processes can be of
possible remedial value to counter a similar disease pathophysiology.
Key words: cardiac hypertrophy, hypertrophic heart rat, microRNAs, apoptosis, cardiogenesis, biomarkers, anti-sense
therapy.
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I. INTRODUCTION
The human body ages naturally and as it does biological
changes occur which do not necessarily mean deterioration
of health leading to death (Berzlanovich et al., 2005). Rather,
these changes may result in accumulated cellular damage
in due course which makes an individual more susceptible
to disease (Lo´pez-Otín et al., 2013). For instance, endothelial
dysfunction due to hypertension, dyslipidaemia, smoking
and oxidative stress can result in atherosclerotic changes
in coronary vessels (Nabel & Braunwald, 2012). Similarly,
cardiovascular risk factors such as insulin resistance,
obesity, hypertension and behavioural risk factors including
depression, smoking and physical inactivity can result in
Alzheimer’s disease and dementia (Barnes & Yaffe, 2011;
Teipel, 2013).
Aging can be viewed from a biochemical perspective
as well. Telomeres protect stem cells from chromosomal
degradation, however with gradual decline of telomerase
activity successive cycles of proliferation result in shortening
of telomere length resulting in decreased proliferation
and cellular aging (Flores & Blasco, 2010). In addition,
several other molecular processes have been suggested to
contribute to aging such as mitochondrial dysfunction,
genomic instability, epigenetic modifications and progenitor
cell depletion (Lo´pez-Otín et al., 2013).
Non-coding ribonucleic acids (ncRNAs) that in the past
were regarded as merely ‘junk’ oligonucleotide sequences
are now an entire research field of interest. MicroRNAs
are one such set of ncRNAs that regulate gene expression
primarily by binding to their complementary mRNA
sequence and influencing gene expression (Esteller, 2011).
Various families of microRNAs are thought to be conserved
during evolution in humans and plants and have been
shown to play an essential role in development, growth
and maintenance (Cuperus, Fahlgren & Carrington, 2011;
Wang et al., 2011; Yi & Fuchs, 2011). Several studies
have suggested that levels of microRNAs change with
time, for example during pregnancy and in age-related
neurodegeneration (Gilad et al., 2008; Aw & Cohen,
2012). Thus researching microRNA-led regulation of gene
expression with time is of importance in the understanding
of mechanisms behind various acquired and heritable
diseases.
One such group of disorders is adaptive cardiac
hypertrophy. It can be a product of physiological or
pathological influences on the structure and function of the
myocardium including varied ventricular mass, measures of
contractile proteins, degree of fibrosis, calcium handling
and neuronal makeover (Hill & Olson, 2008). Cardiac
hypertrophy is an increase in cardiac cell mass which can
ultimately result in fatal cardiovascular events (Levy et al.,
1990; Ghali, Liao & Cooper, 1998). The Framingham Heart
Study identifies left ventricle (LV) hypertrophy as the most
important cardiovascular risk factor after age (Levy et al.,
1990). The adaptation occurs as a compensatory response to
physiological or pathological stress on the myocardium which
leads to growth of terminally differentiated cardiomyocytes
(Grossman, 1980; Frey & Olson, 2003). In either case
hypertrophy results in ventricular dysfunction but not all
individuals exposed to the risk factors have the same degree
of increase in cardiac mass (Gardin et al., 1995). In addition,
numerous clinical studies involving twins and families have
given evidence of the role that heritable genes have in
determining heart size (Mayosi, 2002).
The focus of this review is to describe the involvement of
microRNAs in cardiac growth and development. In addition,
the role of microRNAs will be discussed in the context of
physiological and pathological cardiac hypertrophy. Lastly,
the importance of microRNAs in modern-day medicine in
relation to their value as tools of diagnosis and therapy of
cardiac hypertrophy will be emphasized.
II. CARDIAC HYPERTROPHY: THE GOOD AND
THE BAD
(1) Physiological versus pathological hypertrophy
As the human body ages, the heart goes through various
physiological and pathological alterations. Post-neonatal
cardiac growth and cardiac hypertrophy associated with
pregnancy or regular athletic exercise are part of the natural
growth process. On the other hand incidence of heart
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failure increases with age primarily due to hypertension
and coronary heart disease with associated left ventricular
hypertrophy (Kannel & Belanger, 1991). Hypertrophic
changes are a common denominator in the equation of
cardiac function and have two forms: concentric and
eccentric. Concentric hypertrophy can result from increased
forced contractility particularly in response to higher
peripheral resistance seen in hypertension or valvular stenosis
and after excessive muscular exercise done by wrestlers
and weight lifters (Maillet, van Berlo & Molkentin, 2012).
Eccentric hypertrophy, by contrast, is seen chronically after
an ischaemic episode, in dilated cardiomyopathy, during
pregnancy and in endurance athletes (Maillet et al., 2012).
There are some distinct features differentiating between
physiological and pathological hypertrophy. An increase
in apoptosis, necrosis, type I collagen deposition in the
myocardium, up-regulation of foetal gene expression,
down-regulation of genes encoding contractile protein,
decreased fatty acid oxidation and enhanced glucose
metabolism are hallmarks of pathological hypertrophy
(Bernardo et al., 2010).
microRNAs, not surprisingly regulate various biological
pathways resulting in altered cardiac mass. The complex
signalling pathways recognized to be involved in cardiac
hypertrophy will be discussed later in this review along with
the relevant microRNAs predicted to manipulate them.
(2) An animal model differentiating between
physiological and pathological hypertrophy
The hypertrophic heart hat (HHR) is a rodent model
that develops left ventricular hypertrophy independently
of hypertension (Harrap et al., 2002). The model was
successfully developed by cross breeding the spontaneously
hypertensive rat (SHR) with the Fischer (F-344) rat. A
number of genes potentially associated with concentric
cardiac hypertrophy were demonstrated to be altered
in the HHR following microarray analysis (Dwyer et al.,
2008). For instance, DnaJ homolog subfamily A member
3 (DNAJA3) was overexpressed in young HHRs. DNAJA3
encodes for Ras GTPase-activating protein binding protein
(RasGAP) which has a central role in hypertrophic signalling
(Trentin et al., 2001). Similarly, guanine nucleotide binding
protein gene (GNG5), Rab12 – a Ras (rat sarcoma) oncogene
family member – and mitogen activated protein kinase 1
(MAPK1) were overexpressed, these genes are involved in the
Ras/mitogen-activated protein kinase (MAPK) signalling
pathway that results in cardiac hypertrophy (Dwyer et al.,
2008). Four important genes from the microarray data were
validated via real-time polymeric chain reaction (PCR) and
suggested to be involved with cardiac hypertrophy (Dwyer
et al., 2008). These genes were: natriuretic peptide precursor
type B (NPPB), a marker of left ventricular hypertrophy
(Jaffe, Babuin & Apple, 2006), MAPK1, a downstream
component of the Ras signalling pathway (Heineke &
Molkentin, 2006), Tropomyosin 1 (TPM1), involved in
myofibril assembly (McKeown et al., 2014), and TRAF family
member–associated NF-kB activator (TANK ), activator of
the pro-hypertrophic nuclear factor kB (NF-kB) signalling
pathway (Cabal-Hierro et al., 2014).
An interesting finding has come to light using the
HHR model. It has been revealed that the number of
cardiomyocytes in neonatal HHRs are fewer compared to the
normal heart rats (NHRs) of corresponding age, resulting in
smaller hearts at birth and compensatory hypertrophy as the
rat ages with increased cardiac output (Porrello et al., 2009).
Further evidence points towards apoptosis and early terminal
differentiation of cardiomyocytes with phosphatidylinositol 3
kinase-pyruvate dehydrogenase kinase, isoenzyme 1-protein
kinase B (PI3K-PDK1-PKB/Akt) and MAPK signalling
pathways being up- and down-regulated, respectively, in
HHR neonates, possibly as a protective mechanism against
apoptosis to prevent further reduction in cardiomyocyte
numbers (Porrello et al., 2009). The PI3K-PDK1-PKB/Akt
signalling pathway has been well established as a positive
modulator of physiological hypertrophy but has also been
implicated in pathological hypertrophy (Bernardo et al.,
2010). An increased number of binucleated cardiomyocytes
and decreased cellular proliferation was also noted indicating
an early exit from the cell cycle (Porrello et al., 2009). This
previous research has shown that there is a disturbance in
cell growth and altered apoptotic-signalling mechanisms that
need further investigation.
III. MICRORNAS AT A GLANCE
It was initially believed that 18 microRNAs and their families
make up more than 90% of all cardiac microRNAs in
mice aged 6–8 weeks (Rao et al., 2009). However, with
recent improvements in deep sequencing technology and
the ever-growing microRNA database, there has been an
exponential increase in the number of microRNAs thought
to regulate expression of cardiac genes (Hu et al., 2012). From
the list of common microRNAs (Rao et al., 2009; Hu et al.,
2012), miR-1, miR-27b, miR-30e, let-7i and miR-208a were
found to be differentially expressed during early cardiac
hypertrophy in mice with transverse aortic constriction
(TAC) (Hu et al., 2012). Two of these important microRNAs
are discussed later in this review, miR-1 (Section IV.1) and
miR-208a (Sections IV.2 & VI.3).
Fig. 1 provides an overview of the many microRNAs
that are believed to regulate both normal cardiogenesis and
pathological cardiac hypertrophy as a result of cardiovascular
risk factors and compensatory remodelling.
(1) Processing and function
The role of microRNAs was first described in Caenorhabditis
elegans where silencing of mRNA LIN-14 by LIN-4 at various
time points during growth resulted in normal development
of the worm from an embryo (Lee, Feinbaum & Ambros,
1993). The microRNA was transcribed from the worm’s
own genome and hence it was suggested they have an
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Fig. 1. Regulation of cardiogenesis and cardiac hypertrophy by microRNAs. During cardiogenesis, various cellular processes
regulated by microRNAs result in the formation of a normal neonatal heart from a primitive cardiac tube. This is followed by
physiological growth of the heart to compensate for an increase in demand for cardiac output. However numerous cardiovascular
risk factors can result in variable expression of genes and microRNAs that lead to irreversible pathological hypertrophy. It has been
suggested that dysregulation of certain genes during cardiogenesis results in apoptosis and premature exit of cardiac cells from the
cell cycle. This leads to a reduced number of terminally differentiating cardiomyocytes in the heart of a neonate at birth, resulting
in a smaller heart. The heart thus has to compensate by hypertrophic remodelling, predisposing an individual to cardiovascular
disease, particularly hypertension with consequential irreversible concentric pathological hypertrophy. It is yet to be determined
which microRNAs can result in a smaller heart with reduced number of cardiac cells at birth with consequential compensatory
pathological hypertrophy. These microRNAs may be of interest for future research.
auto-regulatory function in gene expression, which is now
widely accepted.
Most of the mammalian microRNA transcription
sequences are part of introns of protein-coding transcripts
but some are found in exons of non-coding regions
as well (Rodriguez et al., 2004). microRNAs are initially
transcribed by RNA polymerases as longer molecules called
pri-microRNAs in the presence of transcription factors
similar to those involved in protein coding (Lee et al., 2004;
Borchert, Lanier & Davidson, 2006). Pri-microRNAs are
cleaved into smaller sequences called pre-microRNAs by
the protein Drosha, which are further cleaved by the
protein Dicer into microRNAs (Knight & Bass, 2001;
Lee et al., 2003). A select group of folded introns with
conserved splice sites have been identified that have a similar
structure to pre-microRNAs, hence skip being cleaved by
Drosha and are instead further processed by Dicer, thus
suggestive of an alternative pathway of biogenesis for certain
microRNAs (Ruby, Jan & Bartel, 2007). Then a hairpin
loop that joins the complementary strands is removed by
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RNA polymerase III and allows the RNA-induced silencing
complex (RISC) to separate the two strands (Kim & Nam,
2006). Exportin-5, a protein of the nuclear membrane,
transports the pre-microRNA out of the nucleus; knockdown
of this protein results in accumulation of pre-microRNA in
the nucleus (Yi et al., 2003). Similar results can be seen in
tumours with deficient expression of this protein (Melo et al.,
2010).
RISC further acts as a cofactor with the microRNA by
forming a multi-protein RNA-silencing complex (Holley &
Topkara, 2011). The complex binds to a complementary
mRNA and suppresses the function of the corresponding
gene(s) in several ways: blocking initiation and elongation,
forcing premature termination of translation, deadenylation
of mRNAs to prevent their reuse and most importantly
degradation of the mRNA (Eulalio, Huntzinger & Izaurralde,
2008; Filipowicz, Bhattacharyya & Sonenberg, 2008). Most
of the repression mediated by microRNAs is the result
of mRNA decay due to perfect continuous pairing of the
seed region found 2–8 nucleotides from the 5′ end of the
microRNA that is critical for target specificity (Lee & Shin,
2012). If the target mRNA has adequate complimentary
sequences the complex will cleave it, resulting in substantial
repression of the mRNA, otherwise if there is an appropriate
collection of complimentary sequences only translation will
be blocked with demonstrable disruption of the target
sequence leading to a lesser degree of repression (Bartel,
2004; Baek et al., 2008).
(2) Fine tuning of microRNAs
MicroRNAs, being regulators of gene expression, are
in turn regulated through a feedback-loop system that
has components at different levels. RNA-binding proteins
DiGeorge Syndrome critical region gene 8 (DGCR8)
and thyroid hormone binding proteins (TRBP) critically
interact with Drosha and Dicer, respectively, to modulate
microRNA processing (Chendrimada et al., 2005; Han et al.,
2009). Processing is also regulated by stimulatory pathways
and accessory proteins such as LIN-28, p68 and p72
(Winter et al., 2009; Davis-Dusenbery & Hata, 2010; Krol,
Loedige & Filipowicz, 2010). In addition, core proteins of
the microRNA-RISC complex, argonaute RISC catalytic
component (AGO) and trinucleotide repeat-containing
gene 6A protein (GW182) required for efficient mRNA
silencing, are also targets of regulation along with several
modulating factors (Winter et al., 2009; Krol et al., 2010;
Braun, Huntzinger & Izaurralde, 2013).
Editing of the microRNA gene sequence by adeno-
sine deaminases that act on RNAs (ADARs) inhibits
Dicer-mediated cleavage with reduced production of mature
microRNAs that results in more stringent loading of
mature microRNA onto the RISC complex and may
even redirect the complex to another target mRNA
(Tomaselli et al., 2013). Moreover, modifications at the 3′
end of a microRNA such as adenylation, uridylation or
O-methylation can alter its stability in a positive man-
ner (Krol et al., 2010). Interestingly, even an increased
cell density can result in more cell–cell interactions which
increase the efficiency of Drosha and the RISC complex,
thus up-regulating microRNA function (Hwang, Wentzel &
Mendell, 2009). Lastly, in addition to the above-mentioned
regulatory mechanisms there are auto-regulatory feedback
loops in which the mRNA suppressed holds the code
necessary for transcription factors required in biogenesis
of the microRNA upstream (Siomi & Siomi, 2010). An
example is the feedback loop that exists between miR-1
and insulin like growth factor 1 (IGF1) via PKB/Akt.
miR-1 targets IGF1, which in turn down-regulates the
pro-hypertrophic PI3K-PDK1-PKB/Akt signalling path-
way, allowing forkhead family transcription factor Forkhead
box O3a (FOXO3A) to increase expression of miR-1 (Elia
et al., 2009). Overexpression of PKB/Akt and FOXA3A in
neonatal rat cardiomyocytes leads to decreased and increased
expression of miR-1, respectively (Elia et al., 2009).
IV. MICRORNAS REGULATE CARDIOGENESIS
Expression profiling of the developing heart has revealed
that levels of mature microRNAs vary during important
developmental milestones (Cao et al., 2012). Comparison of
the levels between normal and pathological states helps to
identify the role of vital and relevant microRNA congenital
anomalies such as the teratology of Fallot (O’Brien et al.,
2012).
The heart is the first organ to form and it is vital that the
developmental process continues uninterrupted for normal
morphogenesis and function. The primitive heart starts as a
single tube derived from mesodermal cells and is called the
primary heart field (PHF). It also functions as a framework
for cells of the second heart field (SHF), with the two
field cells interacting through several regulated complex
signalling networks resulting in a mature four-chambered
heart (Srivastava, 2006). During embryogenesis various cell
types participate in a complex network of interactions with
specific microRNAs concentrated in a particular cell giving it
a unique functional identity (Small & Olson, 2011). Table 1
lists a number of microRNAs involved in mechanisms of
cardiogenesis and their target genes, which are discussed
below.
(1) miR-1/133a: major players in differentiation and
proliferation
miR-1 is the first and best studied microRNA in cardiogenesis
and is continually expressed from the eighth day (E.8) in
embryonic mice (Cordes & Srivastava, 2009). In vertebrates
miR-1 is transcribed with miR-133 as a cluster from
a common polycistronic transcript (Chen et al., 2005).
Polycistronic transcripts have cistrons (loci) that are expressed
together by the same transcription factor(s). It is suggested
the locus of miR-1/133a duplicated during evolution to
yield three related microRNA clusters; miR-1-1/133a-2,
miR-1-2/133a-1 and miR-206/133b (Chen et al., 2005).
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Table 1. Many microRNAs play a vital role in regulating a range of biological processes necessary for normal progression of
cardiogenesis. miR-1 and miR-133 target numerous genes and affect an array of cellular pathways such as differentiation and
proliferation, which are fundamental processes during cardiac development. Other microRNAs are equally important as they
regulate pathways that ensure the heart develops as a viable organ. + and − indicate a positive or negative regulatory effect,
respectively, of the microRNA on a particular cellular pathway
Pathway miR-1 miR-133 miR-1-2 miR-218a miR-138 miR-143 miR-17-92 miR-499
Differentiation +, Nkx2.5 +, Nkx2.5 +, ISL1
+, α-MHC +, α-MHC
+, WNT
+, FGF
Proliferation −, HAND2 −, SRF +, NELFA
−, CyclinD
Apoptosis −, SRF
−, CyclinD
−, Caspase9
Conduction −, KCNQ1 +, IRX5
−, KCNH2 +, KCND2
Migration +, ROBO1
Maturation +, CSPG2 +, NOTCH1B +, MYH7B
Remodelling +, ADD3
Transcription of these clusters is regulated by serum response
factor (SRF), myocyte enhancer factor 2 (MEF2) and a basic
helix-loop-helix (bHLH) protein, myoblast determination
(MYOD) (Zhao, Samal & Srivastava, 2005; Liu et al., 2007).
miR-1 and miR-133 work in confluence to divert
embryonic stem cell differentiation towards a mesodermal
cell lineage instead of endodermal or neuroectodermal
lineages by reducing the expression of Nkx2.5 and α-myosin
heavy chain (α-MHC) (Takaya et al., 2009). Nkx2.5 is
a homeodomain factor which represses proliferation of
cells in the SHF and outflow tracts (Prall et al., 2007),
whereas α-MHC encodes for contractile content in the
heart after birth. On the other hand, the two microRNAs
work in conflict during maturation of cardiomyocytes
from mesodermal precursor cells with miR-1 fostering and
miR-133 antagonizing the process (Ivey et al., 2008).
Overexpression of miR-1 results in death at E13.5 in mice
(Zhao et al., 2005). The microRNA is suggested to induce
early exit of cardiomyocytes from the cell cycle by limiting
the function of heart and neural crest derivatives expressed
2 (HAND2), a bHLH protein required for growth of the
right and trabeculation of the left ventricle (Zhao et al., 2005).
Overexpression of miR-1 also demonstrates the important
regulatory role it plays in succession of the cardiac cell
lineage. miR-1 promotes differentiation of embryonic stem
cells as well as progenitor cardiac cells into cardiomyocytes
instead of smooth muscle or endothelial cells by suppressing
int/Wingless (WNT) and fibroblast growth factor (FGF)
signalling pathways during early cardiogenesis (Lu et al.,
2013). By contrast, deletion of miR-1-2 from the hearts
of mice resulted in fatal ventricular septal defects in late
embryonic life in half the embryos, with the surviving mutant
hearts exhibiting continuous mitosis whereas the adult heart
undergoes only a single cycle of cellular division immediately
after birth before exiting the cell cycle (Zhao et al., 2007).
However, a study by Wei et al. (2014) demonstrated
that absence of miR-1 did not result in the previously
mentioned cardiac malformations and hence embryonic
lethality, instead the mice developed chamber enlargement
after P12 with all them subsequently dying by P17. A
probable explanation for the later appearance of the fatal
phenotype due to miR-1 suppression found by Wei et al.
(2014) compared to Zhao et al. (2007) is a change in the
gene-editing technology used that allows relatively more
accurate snipping of target sequences with reduced silencing
of nearby genes. However, miR-1 knockout mice suffer
the same fate as their previous counterparts, indicating a
different pathophysiology. A new target gene for miR-1
has been discovered, estrogen-related receptor β (ERRβ)
that is responsible for induction of the foetal cardiac
gene program, including cellular proliferation, glycolysis,
glycogenesis and expression of sarcomere-associated genes
(Wei et al., 2014). It has been suggested that inhibition of
glucose metabolism allows the embryonic heart to transit
into the postnatal stage with β-oxidation of fatty acids as the
predominant source of energy, in addition to expression of
adult sarcomere/contractile proteins instead of foetal genes
(Wei et al., 2014). Therefore the role of miR-1 is crucial during
cardiogenesis and in regulating cardiac cell proliferation,
maturation and metabolism.
A similar disease-state overexpression of miR-1 can be
seen in mutant mice when there is deletion of miR-133a-1
and miR-133a-2 that results in ventricular septal defects
and dilated cardiac chambers (Liu et al., 2008). The small
percentage of mutant mice that do survive to adulthood
eventually die of dilated cardiomyopathy and heart failure
evident by increased cardiac markers of stress: myosin
heavy chain 7 (MYH7), atrial natriuretic factor (ANF ) and
B-type natriuretic peptide (BNP ) (Liu et al., 2008). These
knockout mice had up-regulated expression of SRF and
cyclin D along with increased cardiomyocyte proliferation,
disorganization of sarcomeres, fibrosis and apoptosis (Liu
et al., 2008). Absence of miR-133a in mice also activates
smooth muscle genes due to lack of inhibition of SRF
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resulting in less mature hearts as these genes are normally
activated temporarily during heart tube formation (Liu et al.,
2008).
By contrast, overexpression of miR-133a inhibits
proliferation leading to death from hypoplastic ventricular
walls and septal defects (Liu et al., 2008). However, it has
also been reported that miR-133 promotes proliferation by
inhibition of SRF (Chen et al., 2006). A possible explanation
suggested by Liu et al. (2008) is that SRF can be a
positive and negative regulator of proliferation depending
on the availability of suitable co-factors and external stimuli.
Overexpression of the microRNA also inhibits stress-induced
cardiomyocyte hypertrophy by targeting members of the
Rho family – Ras homolog family member A (RhoA)
and Saccharomyces cerevisiae S288c (Cdc24) – which encode
for GTP-binding proteins involved in cytoskeletal and
myofibrilliar rearrangement (Care et al., 2007). miR-133a
also targets negative elongation factor complex member A
(NELFA), an RNA polymerase II regulator which plays a role
in the activation of transcription of foetal cardiac genes such
as myosin heavy chain 6 (Myh6 ), and Myh7 (Care et al., 2007).
The three targeted genes under physiological conditions
result in cardiac hypertrophy thus suggesting a delicate
balance of cellular proliferation and growth mediated by
miR-133a.
mir-133a is believed to affect several other cellular
pathways. The microRNA prevents apoptosis possibly
through down-regulating caspase-9, regulates extracellular
matrix of the myocardium by targeting connective tissue
growth factor (CTGF) and controls metabolism by targeting
kruppel-like factor 15 (KLF15) which in turns limits glucose
transport 4 (GLUT4) (Liu & Olson, 2010).
(2) Other significant microRNAs
mir218-a is believed to be involved in cardiac morphogenesis
with overexpression resulting in inadequate heart tube
looping, an uneven ventricle wall thickness and severally
dysmorphogeneic atrial chambers which are sometimes
merely string-like in structure (Chiavacci et al., 2012).
miR-218a and the host gene slit homolog 2 (SLIT2)
are regulated by T-box transcription factor (TBX5)
with microRNA expression directly proportional to
transcription factor levels (Chiavacci et al., 2012). miR-218a
is underexpressed in very early stages of heart development
but later allows passage of precursor cells within the heart
fields by targeting roundabout axon guidance receptor
homolog 1 (ROBO1) (Chiavacci et al., 2012). Overexpression
of the microRNA results in delayed migration and the
above-mentioned cardiac defects whereas down-regulation
did not affect cardiogenesis indicating that other microRNAs
play a role in this complex process (Chiavacci et al., 2012).
miR-138 has been implicated in ventricle development
as well. It is expressed for a limited time during cardiac
looping between 24 and 34 h post-fertilization in mice
(Morton et al., 2008). The microRNA allows maturation
of ventricular cardiomyocytes by limiting synthesis of
retinoic acid dehydrogenase, which disrupts the retinoic
acid signalling pathway (Morton et al., 2008). This in turn
prevents expression of two genes involved in formation of
the atrioventicular canal from spreading into the maturing
ventricle: chondroitin sulfate proteoglycan 2 (CSPG2), which
encodes for a cell adhesion protein versican, and Notch
homolog 1b translocation-associated (Drosophila) (NOTCH1B)
(Morton et al., 2008).
Another microRNA, miR-143, has shown to be active in
ventricular myocardial cells on the fifth day of embryonic life
of zebra fish (Brachydanio rerio) where it represses the function
of cytoskeletal F-actin capping protein encoded by adductin3
(ADD3) which is involved in rearranging F-actin allowing
cytoskeletal growth and cellular remodelling (Deacon et al.,
2010). The microRNA can also be found in the heart tube of a
zebra fish 36–48 h after fertilization where it is believed to be
involved in regulating ventricular contractions (Deacon et al.,
2010). Deletion of the microRNA results in atrial dilatation
and dysfunctional ventricles in fish (Deacon et al., 2010).
A cluster of microRNAs collectively named miR-17-92 is
activated downstream of the bone morphogenetic protein
(BMP) signalling pathway and is believed to facilitate
differentiation of cardiac precursor cells in the SHF by
repressing a progenitor gene; insulin gene enhancer protein
ISL-1 (ISL1) (Wang et al., 2010b). Overexpression of the
microRNA cluster affects development of the outflow tract
whereas deletion results in fatal hypoplastic ventricular
walls with septal defects (Wang et al., 2010b). Moreover,
miR-17-92 allows cardiac cells to proliferate at any age
including during embryonic and post-natal development;
overexpression of the cluster thus is protective against
myocardial infarctions, whereas miR-17-92 knockout mice
had evidence of compensatory cardiac cell hypertrophy with
decreased numbers of cardiomyocytes (Chen et al., 2013). In
vitro experiments on rat neonatal cardiomyocytes revealed
phosphatase and tensin homolog (PTEN ) to be the target
gene (Chen et al., 2013).
During development of the heart, MYH7 is transiently
expressed until birth and encodes for a slow ATPase
β-myosin heavy chain (β-MHC), then another protein
α-MHC, which is a fast ATPase coded by MHY6 , takes
over as the predominant MHC in cardiac cells, this
transition is mediated by circulating thyroid hormone
(Morkin, 2000). In addition, these genes also express intronic
microRNAs collectively called MyoMirs: miR-208a and
miR-208b, encoded by MYH6 and MYH7, respectively
(Callis et al., 2009). A third microRNA of this group, miR-499,
encoded by MYH7B is believed to up-regulate β-MHC and
allows ventricular maturation (Fu et al., 2011). MyoMirs are
expressed alongside their host genes thus regulate myosin
content of cells and therefore effective muscle contraction
(Liu & Olson, 2010). Hence the role of miR-208b is vital
during cardiogenesis and thereafter to allow the required
levels of myosin to develop for the contractile machinery.
These microRNAs will be discussed further in Section VI.3.
microRNAs, as expected, have an important role to
play in development of the cardiac conduction system
as well. miR-1-2 knockout mice which survive the
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embryonic period die of sudden onset arrhythmias with the
electrocardiogram (ECG) showing bradycardia, a shortened
PR interval and a widened QRS complex (Zhao et al.,
2007). A proposed mechanism is that a transcription
factor Iroquois homeobox 5 (IRX5) is up-regulated which
in turn down-regulates potassium voltage-gated channel
shal-related subfamily member 2 (KCND2) which encodes
for potassium channels (Zhao et al., 2007). Similarly,
miR-133a also targets genes encoding for potassium channels
and associated subunits: potassium voltage-gated channel
KQT-like subfamily member 1 (KCNQ1) and potassium
voltage-gated channel subfamily H member 2 (KCNH2)
with overexpression of the microRNA resulting in QT
prolongation predisposing to arrhythmias and fibrillation
(Cordes & Srivastava, 2009; Liu & Olson, 2010).
(3) Effects of microRNA global deletion
Another way to study the influence of microRNAs is to
prevent their biogenesis in selective cells and analyse the
compound effects of universal deletion. Inhibition of Dicer
from epicardial cells in embryonic mice results in pericardial
haemorrhage with an anomalous coronary vasculature by
E18.5 (Singh et al., 2011). Mesothelial progenitor cells mature
into epicardial cells by E10.5 in mouse embryos, which
further differentiate into various cellular types including
vascular smooth muscle cells in a transformation process
termed epithelial-to-mesenchymal transition (EMT) (Singh
et al., 2011). Absence of Dicer results in overexpression of
E-cadherin and failure of zona occludens 1 (ZO-1), a tight
junction protein, to move away from the cell surface thus
keeping the cells adhered to each other and inhibiting EMT
(Singh et al., 2011). Additionally, a smooth muscle cell marker
smooth muscle cell 22 (SMC22) is weakly expressed in the
developing coronary vasculature further confirming failure
of the transition process (Singh et al., 2011). An abnormal
vasculature can predispose to heart failure (Uysal et al., 2014).
Cardiac-specific Dicer knockout mice die within 4 days
of birth with histologically evident ventricular dilatation,
disorganized sarcomeres and an altered measure of
contractile protein expression (Chen et al., 2008). In addition,
cardiac function was severely diminished in these mice
indicative of dilated cardiomyopathy with eventual heart
failure (Chen et al., 2008). Additionally, adolescent and adult
mice with induced cardiac-specific Dicer deletion had an
escalating increase in expression of foetal genes along with
increasing myocardial inflammation, chamber remodelling,
dilatation with myocardial hypertrophy, and decreasing
cardiac function, all characteristics of progressive heart
failure (da Costa Martins et al., 2008). Similarly in a later
study, deletion of cardiac Dicer was lethal in embryonic mice.
These mice died by E13.75 due to ventricle septal defects
associated with the aorta and pulmonary artery exiting from
the right ventricle (Saxena & Tabin, 2010). Sema domain
immunoglobulin domain (Ig) short basic domain secreted
(semaphorin) 3c (SEMA3C) and its regulatory transcription
factor were up-regulated in these mutant mice; they play a
vital role physiologically in positioning outflow tracts through
guiding axons of neuronal cells and promoting migration
of neural crest cells (Saxena & Tabin, 2010). In addition,
apoptosis is important for cardiogenic remodelling of outflow
tracts and was diminished in these knockout mice compared
to wild-type mice (Saxena & Tabin, 2010).
Another global Dicer knockdown investigation had similar
results showing that murine neural crest cells destined
towards cardiogenesis lead to cardiovascular malformations
such as ventricular septal defects, great vessel outlets in the
right ventricle and misplaced subclavian and carotid arteries
(Huang et al., 2010). Interestingly, migration patterns of the
neural crest cells into the outflow tracts and cardiac fields
from the third, fourth and sixth pharyngeal arches were
affected instead of consequential apoptosis in the absence of
Dicer (Huang et al., 2010).
V. POSTNATAL HYPERTROPHY: REGULATION
OF CELLULAR PROLIFERATION
It is of general belief that cardiomyocytes lose their
regenerative and proliferative capacity at birth resulting in
physiological hypertrophy, which is the hallmark of postnatal
cardiac growth. However, it was revealed that neonatal rat
hearts continue to proliferate up to 7 days following birth
(Porrello et al., 2011b). In addition, a population of cardiac
progenitor cells called cardiac side population (CSP) have
been identified which have the potential to differentiate into
mature cardiac cells (Pfister et al., 2005).
The miR-15 family has been shown to be up-regulated
in mouse hearts between 7 and 14 days of age and represses
expression of cell cycle genes, particularly checkpoint
kinase 1 (CHEK1), which halts cardiomyocytes in the
G2/M transition phase of the cell cycle (Porrello et al.,
2011a). The family includes miR-15a, miR-15b, miR-16-1,
miR-16-2, miR-195 and miR-497 that are clustered on three
different chromosomes with similarities in sequences of their
mature microRNAs (Porrello et al., 2011a). Overexpression
of miR-195 in primary neonatal cardiac cells results in
hypertrophy and binucleation with ventricular septal defects
and cardiac hypoplasia seen in mice (Porrello et al., 2011a).
Alternatively, suppression results in increased numbers of
cardiomyocytes undergoing a mitosis that was insufficient for
the cells to entirely progress through the cell cycle, suggesting
other regulatory mechanisms (Porrello et al., 2011a).
Similarly, there are several cyclins and cyclin-dependent
kinases (CDKs) particularly CDK2 and CDK6 that
were shown to be down-regulated in 6-day-old postnatal
cardiomyocytes and are targets of miR-29, miR-30
and miR-141 (Zhang et al., 2013b). The microRNAs
induce senescence in postnatal cardiomyocytes whereas
suppression by anti-microRNA treatment in primary
neonatal cardiomyocytes at 1 day of age resulted in increased
expression of cyclin A2 (CCNA2) with more cells entering
the cell cycle (Zhang et al., 2013b). Moreover, expression of
miR-141 along with miR-137 was also decreased in cardiac
cells that had regained proliferative capabilities (Zhang et al.,
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2010). Unfortunately a great deal of research is still required
to fill in the gaps in our understanding of the role of
microRNAs in physiological cardiac hypertrophy occurring
as part of the normal growth process.
VI. MICRORNAS IN PATHOLOGICAL
HYPERTROPHY
Pathological hypertrophy is a precursor to heart failure and
can occur as a result of various stressors on the myocardium.
Fortunately, cardiac hypertrophy can be induced in a
laboratory setting by banding the aorta as it descends
which forces the myocardium to adapt to an increase in
peripheral resistance, or by stimulating cardiac cells using
various biochemical agonists that trigger the hypertrophic
signalling pathways. Much research is being done to
understand the complexity of microRNA-led regulation
of cardiac hypertrophy. Microarray analysis has revealed
several microRNAs that are up- or down-regulated in the
hearts of mice subjected to TAC and cultured rat neonatal
cardiomyocytes treated with a hypertrophic agonist such
as phenylephrine (PE) or transfected with recombinant
adenovirus (van Rooij et al., 2006; Sayed et al., 2007;
Tatsuguchi et al., 2007). For instance, expression of miR-21
and miR-18b was down-regulated during hypertrophic
changes whereas introduction of the microRNAs inhibited
the remodelling process (Tatsuguchi et al., 2007). Another
study demonstrated that overexpression of miR-195 in
transgenic mice results in cardiac hypertrophy (van Rooij
et al., 2006). Here we discuss some microRNAs that are of
general interest and have the potential to be of therapeutic
value. Table 2 provides a summary of the microRNAs
involved in mechanisms of pathological hypertrophy and
their target genes.
(1) microRNA-378
miR-378 has been implicated to have a role in cardiac
hypertrophy through inhibiting the Ras signalling pathway.
This pathway is activated by various receptors and associated
ligands grouped under receptor tyrosine kinases (RTKs),
including insulin-like growth factor receptor (IGFR), and
G protein coupled receptor (GPCR), the ligand for which
more importantly in hypertrophy is angiotensin II (Heineke
& Molkentin, 2006). Two distinct pathways further mediate
pro-hypertrophic signalling through Ras: (i) v-raf-1 murine
leukaemia viral oncogene homolog 1 – dual specificity
mitogen-activated protein kinase kinase 1 – extracellular
signal-regulated kinase 1/2′′ (Raf1-MEK1/2-ERK1/2)
(ERK1 and 2 are also known as MAPK3 and 1, respectively);
(ii) PI3K-PDK1-AKT. AKT inhibits glycogen synthase
kinase (GSK)-3β, with both paths resulting in activation of
nuclear factor of activated T-cells (NFAT) and transcription
of cardiac hypertrophy genes (Proud, 2004; Heineke &
Molkentin, 2006). T
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miR-378 blocks growth factor receptor bound protein
2 (GRB2) which plays an important role in activation of
the Ras pathway by being recruited to the cell membrane
and interacting with son of sevenless (SOS); levels of the
protein were increased in patients with heart failure and
in cardiomyocytes stimulated by PE (Nagalingam et al.,
2013). Transgenic mice with haploinsufficiency of GRB2
had attenuated compensatory responses to TAC (Zhang
et al., 2003). Inhibition of Grb2 results in down-regulation of
both mediating pathways, which was evident by decreased
phosphorylation of ERK1/2 and p70S6 (a kinase regulating
translation), decreased accumulation of NFAT in the
nucleus and increased phosphorylation of AKT/GSK-3β
(Nagalingam et al., 2013). By contrast, inhibition of miR-378
induced expression of foetal genes resulting in increased
levels of skeletal actin, NPPB and ANF in the presence
of PE stimulation (Nagalingam et al., 2013). Another study
validated, in addition to GRB2, miR-378 targets IGFR1,
ERK2 and kinase suppressor of Ras (KSR1), a scaffold protein
on which ERK2 activation relies (Ganesan et al., 2013).
Synergistic to the function of the miR-15 family, miR-378
has also been implicated as a potential regulator of the
cardiac cell cycle during postnatal life through repression
of IGF1R from the seventh postnatal day onwards when
expression of the microRNA is induced (Knezevic et al.,
2012). The IGF1R signalling cascade is associated with
proliferation of cardiomyocytes during foetal life and DNA
synthesis in neonatal cells, hence it is important for the
growth and survival of cardiac cells (Kardami, 1990). A
double feedback-loop arrangement exists between miR-378
and IGF1, hence postnatal induction of miR-378 can be a
negative regulator of the cell cycle (Knezevic et al., 2012).
The role of miR-378 in apoptosis is rather inconclusive.
As previously mentioned, miR-378 functioned as a negative
regulator of the cell cycle and induced apoptosis (Knezevic
et al., 2012) whereas another investigation has validated
caspase-3 as a target of the microRNA and hence is protective
of ischaemia-induced apoptosis in cardiomyocytes (Song &
Yuan, 2012). Ganesan et al. (2013) observed that during in vivo
experiments, miR-378 did not induce apoptosis, although it
was observed in cultured cells suggesting that cells are more
sensitive to apoptotic stimuli in vitro.
(2) microRNA-34a
miR-34a belongs to the miR-34 family, which also includes
miR-34b and miR-34c. It has been investigated on numerous
occasions to play a role in aging and cancer by regulating
cellular proliferation and apoptosis. miR-34a can influence
the cell cycle through suppression of many genes including
sirtuin1 (SIRT1), a regulator of the cell cycle and senescence
(Yamakuchi & Lowenstein, 2009). miR-34a expression can
be induced by p53 as a result of oxidative stress and DNA
damage, the microRNA in turn inhibits SIRT1 which then
allows p53 to remain acetylated resulting in arrest of the
cell cycle and apoptosis (Yamakuchi & Lowenstein, 2009).
Human aortic endothelial cells transfected with miR-34a
precursor displayed a higher number of endothelial cells in
the G1 phase of the cell cycle indicating senescence and
decreased proliferation; in addition these cells had reduced
growth (Ito, Yagi & Yamakuchi, 2010; Badi et al., 2015).
An interesting observation was that expression of miR-34a
increased with age in untransfected cells and also in the
hearts of 32-weeks-old mice compared to 4 weeks old which
suggests the microRNA has a role in aging, characterized by
increased apoptosis and decreased cell proliferation (Ito et al.,
2010).
Not surprisingly, another target identified is an
anti-apoptotic gene aldehyde dehydrogenase 2 (ALDH2),
suppression of which after a myocardial infarction (MI) and
hypoxia-induced miR-34a expression resulted in increased
apoptosis (Fan et al., 2013). miR-34a levels in the serum
of post-MI patients and rat models were further elevated
establishing the importance of the role of this microRNA
in cardiac dysfunction following ischaemia (Fan et al.,
2013). Increased apoptosis results in a hastened progression
to dilated cardiomyopathy instead of compensatory
hypertrophy with inevitable heart failure. Inhibition of
ALDH2 results in activation of the MAPK signalling pathway
with increased activity of c-Jun N-terminal kinase (JNK) and
p38 leading to apoptosis (Zhang et al., 2011). A complex
network of intercommunicating proteins is induced following
activation of MAPK-mediated apoptosis, which is beyond
the scope of this review.
Increased glucose levels can also induce apoptosis in
cardiac cells, which may explain the cellular pathogenesis
behind diabetic cardiomyopathy. H9c2 cells grown
in high-glucose culture media had elevated levels of
miR-34a expression with suppressed levels of yet another
anti-apoptotic protein, B-cell CLL/lymphoma 2 (BCL2),
resulting in apoptosis (Zhao et al., 2013). Bcl2 has been
widely investigated as having an important role in regulating
apoptosis and is the target of other microRNAs such as
miR-195, miR-24 and miR-365 (Singh & Saini, 2012).
Another study demonstrated that aged mice had
elevated levels of miR-34a expression with increased
cardiac fibrosis, hypertrophy, shorter telomeres and
increased apoptosis whereas inhibition of miR-34a in
18-months-old mice resulted in a reduced number of dead
cells and miR-34a knockout mice demonstrated reduced
age-associated deterioration of cardiac function (Boon
et al., 2013). In addition, mouse models of induced acute
myocardial infarction (AMI) with inhibition of miR-34a
had improved recovery, evident by decreased fibrosis and
improved cardiac contractile function (Boon et al., 2013). The
target identified and validated in this study was phosphatase
1 nuclear-targeting subunit (PNUTS), which has surfaced as
an important component of the DNA damage response and
positively regulates cell survival (Boon et al., 2013; Loffredo,
Pancoast & Lee, 2013).
Similarly, cardiac fibroblasts isolated from the AMI mouse
model demonstrated induction of transforming growth factor
β1 (TGF-β1) in response to ischaemia with increased
expression of miR-34a which targets mothers against
decapentaplegic homolog 4 (SMAD4) resulting in cardiac
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fibrosis (Huang et al., 2014). Activation of TGF-β1 transforms
fibroblasts into cardiac fibroblasts and stimulated expression
of miR-34a, which in turn inhibited SMAD4 and allowed
collagen deposition by the TGF-β1 signalling pathway in a
positive feedback loop (Huang et al., 2014). Overexpression of
miR-34a resulted in increased cardiac fibroblast proliferation
and migration, indicating that the microRNA promotes
cardiac fibrosis in response to a myocardial infarction (Huang
et al., 2014). In another study, SMAD4 knockout mice had
cardiac hypertrophy, decreased contractile function and
increased fibrosis as a result of up-regulated ERK1/2 and
MEK1 expression (Wang et al., 2005).
In relation to cardiac hypertrophy, it has been shown
that inhibition of the miR-34 family and not miR-34a
alone can improve the outcome in mouse models with
pre-existing cardiac dysfunction and remodelling (Bernardo
et al., 2012). Mice subjected to a myocardial infarction
developed hypertrophy and that were then treated with
anti-miR-34 on day 2 after infarction had slower progression
of ventricular wall remodelling (hypertrophy to dilatation,
decreased atrial enlargement, lung congestion and fibrosis)
at 8 weeks of age compared to control mice (Bernardo et al.,
2012). Similar results were observed in mice subjected to
pressure overload via TAC that developed hypertrophy with
subsequent systolic dysfunction at 5 weeks of age and were
then treated with anti-miR-34 for a further 6 weeks (Bernardo
et al., 2012).
(3) MyoMirs: microRNA-208
Myo-microRNAs that were discussed in Section IV.2
play a vital role in switching expression of α-MHC
to β-MHC. Stressful conditions and disease states such
as hypothyroidism induce expression of β-MHC that
consequently results in impaired cardiac contraction and
function (Morkin, 2000). Overexpression of miR-208a results
in concomitant expression of β-MHC and miR-208b
whereas blocked expression has an opposite effect thus
indicating the dominant role of miR-208a in this
microRNA family (Callis et al., 2009). miR-208a/b-led
repression of thyroid hormone receptor associated protein
1 (THRAP1), a triidothyronine (T3) receptor co-regulator,
and ‘myostatin’ allow the heart to undergo compensatory
hypertrophy and fibrosis in response to stress stimuli (Callis
et al., 2009). Thyroid hormone promotes expression of
several genes enhancing inotropic (contractile) function
of the heart including sarco/endoplasmic reticulum
Ca2+-ATPase-2a (SERCA2A), α-MHC, β1-adrenergic
receptor, Na+/K+-ATPase and K+ channels while
suppressing β-MHC (Li et al., 2014b). Myostatin prevents
cardiac hypertrophy by inhibiting AMP-activated kinase
(AMPK) through the transforming growth factor-β-activated
kinase 1 (TAK1); on the other hand, AMPK activation is seen
in myocardial infarction, left ventricular pressure overload
and cardiac hypertrophy (Biesemann et al., 2014). Hearts
of miR-208a transgenic mice were larger, had enlarged
chambers with thick ventricular myocardium, increased
cell size and poor cardiac function (Callis et al., 2009). A
previous study demonstrated that cultured cardiac cells
under cyclical mechanical stress created by a vacuum
induced TGF-β1, which in turn stimulated miR-208a and
downstream β-MHC expression (Wang et al., 2013).
This microRNA also delicately influences cardiac
conduction; ECG recordings of miR-208a transgenic mice
demonstrated an increased PR interval which indicates
an atrioventricular (AV) heart block while loss-of-function
mice had absent P waves suggesting atrial fibrillation (Callis
et al., 2009). A proposed mechanism for arrhythmias in the
loss-of-function model of miR-208a is increased levels of
transcription factor GATA-binding protein 4 (GATA4) with
decreased expression of homeodomain-only protein (HOP)
and subsequently connexion-40, a gap junction protein that
allows propagation of electric activity (Callis et al., 2009).
miR-208 has also been shown to inhibit mediator complex
subunit 13 (MED13) which is required for transcription
of genes and can reduce expression of metabolic genes as
explained earlier (Carrer et al., 2012).
(4) microRNA-214
miR-214 has been shown actively to induce cardiac hyper-
trophy in vivo and in vitro by directly targeting enhancer of
zeste homolog 2 (EZH2), a major histone methyltransferase
belonging to the polycomb repressor complex 2 (PRC2)
(Yang et al., 2013). EZH2 allows normal growth of cardiac
progenitor cells by stabilizing cardiac gene expression and
down-regulating expression of skeletal muscle genes via
suppressing a homeodomain transcription factor gene, sine
oculis homeobox homolog 1 (SIX1), thus preventing hyper-
trophy of cardiac cells in response to stress (Delgado-Olguin
et al., 2012). miR-214 and EZH2 expression levels were anal-
ysed in cardiac hypertrophy rat models with a constricted
abdominal aorta and cultured cardiomyocytes treated
with PE to induce hypertrophy. Results of both experi-
ments demonstrated increased expression of miR-214 with
decreased quantities of EZH2 mRNA and protein (Yang et al.,
2013). Overexpression of miR-214 in PE-treated cultured
cardiac cells resulted in increased cell size and surface area
along with elevated levels of hypertrophic markers actin alpha
1 skeletal muscle (ACTA1), MYH7 and natriuretic peptide
A (NPPA), whereas suppression of the microRNA had the
opposite effect (Yang et al., 2013). Similarly, overexpression
of miR-214 in transgenic mice resulted in hypertrophy at
3 months of age with sudden death between 6 and 12 months
due to cardiac dysfunction including increased ventricular
diameter, thin chamber walls and a progressively decreasing
ejection fraction (Yang et al., 2014). By contrast, suppression
of miR-214 by an injectable complementary antagonist
in mice with transverse aortic constriction resulted in a
lesser degree of hypertrophy and associated fibrosis with
unaffected cardiac function (Yang et al., 2014).
(5) microRNA-19a/b
Another microRNA family, miR-19a/b that is part of
miR-17-92 cluster, has been shown to target multiple
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pathways that result in cardiac hypertrophy and induce
apoptosis of cardiac cells during stress. Expression of
an anti-hypertrophic gene muscle atrophy F-box protein
(ATROGIN-1) during physiological conditions inhibits the
calcineurin/nuclear factor of activated T-cells (CN-NFAT)
signalling pathway through ubiquitin-mediated proteolysis
and thus prevents cardiac hypertrophy (Li et al., 2004).
CN-NFAT is a pro-hypertrophic signalling pathway that is
activated by cytosolic Ca2+ from the endoplasmic reticulum
(Carren˜o et al., 2006). ATROGIN-1 also targets charged
multi-vesicular body protein 2B (CHMP2B), which is part
of an endosomal sorting complex (ESCRT), thus promoting
autophagy and preventing apoptosis (Zaglia et al., 2014).
Another protein, muscle ring finger protein 1 (MURF1)
inhibits agonist-stimulated protein kinase C (PKC)-mediated
signalling pathway by interacting with the receptor for
activated protein kinase C (RACK1), whereas activation
of this pathway leads to cardiac cell hypertrophy (Arya et al.,
2004). Overexpression of miR-19a/b results in suppression
of ATROGIN-1 and MURF1 which in turn up-regulates
associated pathways leading to increased cardiomyocyte size
along with elevated levels of cardiac hypertrophic markers
(Song et al., 2014). In addition, miR-19a/b was found to
promote proliferation of neonatal cardiac cells by targeting
PTEN, a prohypertrophic and tumour suppressor gene, in
conjugation with its role as a member of the miR-17-92
cluster (Chen et al., 2013).
On the other hand, miR-19a/b up-regulates αCrystallin-B
(αCryB) through activation of the CN-NFAT signalling
pathway during agonist-induced stress on cardiomyocytes
(Song et al., 2014). αCryB is an anti-apoptotic gene and
calcineurin-mediated activation is cardio-protective during
cellular stress (Bousette et al., 2010). Another pro-apoptotic
protein ‘Bim’ was down-regulated by overexpression of
miR-19a/b, which along with αCryB improved cardiac
cell survival against endoplasmic reticular stress (Song et al.,
2014). In contrast to calcineurin activation of NFAT,
stress-activated protein kinases (SAPKs), p38 and MAPK
8 and 9 (JNK 1 and 2), which are part of the MAPK
signalling pathway, are negative regulators with evidence
suggesting a balance in activation (dephosphorylation) and
deactivation (phosphorylation) of the nuclear factor by the
two signalling pathways (Molkentin, 2004).
(6) microRNA-350
Overexpression of miR-350 during later stages of the
hypertrophic response to TAC was observed, leading
to decreased expression of p38 and MAPK8/9 with
increased translocation of dephosphorylated NFAT into the
nucleus (Ge et al., 2013). Cultured H9c2 cells 48 h after
transfection with a miR-350 vector exhibited up-regulation
of hypertrophic markers, a gradual change in morphology
from spindle to polymorphic, and increased cell surface area,
however at the same time they were also observed to shrink
in size, suggestive of the apoptosis seen during the later
stages of hypertrophy, dilated cardiomyopathy and heart
failure (Ge et al., 2013). These results suggest that miR-350 is
expressed during the transition phase of cardiac remodelling
in response to pressure overload, that is from hypertrophy
to dilated cardiomyopathy and eventually death (Ge et al.,
2013).
(7) microRNA-23a
The CN-NFAT signalling pathway can trigger expres-
sion of miR-23a. In response to stressful stimuli,
calcineurin-activated NFAT binds to the promoter region of
miR-23a≈27a≈24-2 resulting in expression of miR-23a and
subsequent cardiac hypertrophy (Lin et al., 2009). miR-23a
suppresses FOXO3A, which has a role in numerous cellular
and biological process including cardiac hypertrophy (Wang
et al., 2012). FOXO3A induces transcription of an antiox-
idant enzyme catalase which neutralizes reactive oxygen
species (ROS) resulting in down-regulation of myocardian
(MYOCD), a cofactor for SRF, hence preventing hypertro-
phy (Tan et al., 2008). Another target of miR-23a in addition
to FOXO3A is MURF1, which as previously explained is
an anti-hypertrophic protein and thus the microRNA can
convey a hypertrophic signal downstream of stress-induced
calcineurin activation (Lin et al., 2009).
(8) microRNA-328
Another microRNA, miR-328, when overexpressed in trans-
genic models, cultured cells or mouse hearts with induced
hypertrophy suppresses its target gene, SERCA2A, which
in turn results in increased intracellular calcium and acti-
vation of CN-NFAT signalling pathway (Li et al., 2014a).
SERCA gene isoforms 1–3 levels gradually increase and then
decrease with age with SERCA2A being the primary tran-
script during cardiogenesis and encoding for Ca2+-ATPase
pumps in the sarco/endoplasmic membrane that transport
Ca2+ into the sarco/endoplasm resulting in muscle relax-
ation (Arai, Matsui & Periasamy, 1994). Thirty-week-old
miR-328 transgenic mice display considerably hypertro-
phied hearts with shortened, hyper-contracted sarcomeres
evident of increased intracellular calcium along with struc-
tural disorganization of myofilaments (Li et al., 2014a).
(9) microRNA-22
miR-22 targets many genes involved in cardiac hypertrophy,
cardiomyocyte survival and cardiac aging. miR-22 was
shown to repress PTEN , which is a negative regulator of
PI3K, resulting in activation of the pro-hypertrophic PKB
signalling pathway evident by increased cell size and elevated
markers of hypertrophy in cultured cells (Xu et al., 2012).
As expected, attenuation of miR-22 resulted in decreased
hypertrophic changes in response to PE and angiotensin-II
stimulation (Xu et al., 2012). The absence of miR-22 also
predisposes the heart to chamber dilatation and dysfunction
during pressure overload with a rapid transition through
the compensatory hypertrophic phase (Gurha et al., 2012).
The fast changeover is due to decreased suppression of
purine-rich element binding protein B (PURB) that in turn
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inhibits transcription of positive cofactors of SRF such as
MYOCD and also through direct inhibition of cardiac
genes that encode for sarcomeric/contractile proteins (Gurha
et al., 2012). Important genes regulated by SRF including
SERCA2A, which as mentioned previously is responsible for
Ca2+ handling in muscle cells, and MHY7, which encodes
for the required myosin content during compensatory
hypertrophy, were down-regulated (Gurha et al., 2012).
In addition, miR-22 suppresses SIRT1 and histone
deacetylase 4 (HDAC4); a cofactor of the MEF2 transcription
factor family (Huang et al., 2013). Mice lacking miR-22 had
dilated cardiomyopathy earlier than expected instead of a
physiological hypertrophy in response to functional stress by
various stimuli (Huang et al., 2013). As expected, transgenic
mice overexpressing miR-22 had hypertrophic hearts with
increased SRF and decreased levels of caveolin-3 (CAV3), an
inhibitor of hypertrophy (Gurha et al., 2012).
Overexpression of miR-22 in cardiac fibroblasts and
vascular smooth muscle cells led to suppression of mimecan, a
secretory protein, which resulted in increased chemotaxis and
senescence thus playing an important role in cardiac aging
(Jazbutyte et al., 2013). Expression levels of the microRNA
showed a progressively upward trend with age and increased
cardiac fibrosis later in life in conjugation with its role of
targeting mimecan (Jazbutyte et al., 2013). Thus, the role
of miR-22 appears to be crucial in cardiac morphological
makeover in reaction to stress with knockout mice progressing
to dilated cardiomyopathy with characteristic cellular death
and fibrosis instead of compensatory hypertrophy (Huang &
Wang, 2014).
(10) microRNA-155
Interestingly, cardiac hypertrophy can also be induced by
paracrine stimuli. Macrophages express high quantities
of miR-155 in response to inflammation through
Toll-like receptors (TLRs) which stimulates myeloid
differentiation factor 88 (MyD88) or TIR-domain-containing
adapter-inducing interferon-β (TRIF)-dependent pathways
(O’Connell et al., 2007). In the absence of miR-155
in macrophages, knockout mice had decreased cardiac
inflammation, hypertrophy and dysfunction to pressure
overload by TAC, whereas bone marrow transplant restored
miR-155 function (Heymans et al., 2013). In addition,
ventricular cardiomyocytes allowed to flourish in growth
media initially used to culture macrophages injected with
miR-155 antago-microRNA showed attenuated growth
suggesting cytokine involvement (Heymans et al., 2013).
The microRNA target identified was suppressor of
cytokine signalling 1 (SOCS1) (Heymans et al., 2013), which
inhibits janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway-mediated hypertrophy
and inflammation (Shi & Wei, 2012). It is believed that
phosphorylated STAT3 in macrophages phosphorylates
STAT3 in cardiomyocytes through paracrine signalling and
induces hypertrophy (Heymans et al., 2013).
Expression of miR-155 in cardiomyocytes was recently
validated as opposed to previous views. Absence or
inhibition of miR-155 in knockout mice resulted in decreased
hypertrophy and cardiac remodelling with slow progression
to dilated cardiomyopathy in response to TAC and
transgenic calcineurin activation (Seok et al., 2014). miR-155
targets jumonji AT-rich interactive domain 2 (JARID2) in
cardiac cells (Seok et al., 2014), which previously has been
shown to interact with the retinoblastoma protein (Rb) to
further suppress E2 transcription factors (E2F ) function with
consequently reduced expression of cyclin D1, cyclin D2 and
Cdc2 in the cell cycle and hence decreased proliferation (Jung
et al., 2005). The miR-155-JARID2-cardiac hypertrophy axis
needs further exploration.
(11) microRNA-489
miR-489 is equally expressed in all cardiac cell types and
is anti-hypertrophic by targeting MYD88, an important
adaptor protein in the TLR-4 mediated NF-kB activation
pathway which contributes to the development of cardiac
hypertrophy and promotes apoptosis (Ha et al., 2006). In
vitro, knockdown of the microRNA promoted cardiomyocyte
hypertrophy after angiotensin II stimulation whereas
overexpression led to reduced cell surface area and decreased
expression of hypertrophic markers (Wang et al., 2014).
Similar results were seen in transgenic models overexpressing
miR-489 and knockdown with antago-microRNAs (Wang
et al., 2014). miR-489 in turn is regulated by a long noncoding
RNA (lncRNA) named cardiac hypertrophy-related factor
(CHRF), which binds directly to the microRNA and is found
in cardiac cells during angiotensin II-stimulated hypertrophy,
in the hearts of mouse models with constricted aortas and in
cardiac tissue from human patients with heart failure (Wang
et al., 2014). Thus the axis of CHRF-miR489-MYD88 has
the potential for therapeutic application in which presence
of a microRNA may improve cardiac function.
VII. DIAGNOSTIC AND THERAPEUTIC VALUE
(1) microRNAs are potential biomarkers
microRNAs can be found circulating in the plasma similar
to protein biomarkers that may be specific to a disease
or the underlying pathology (Reid, Kirschner & van
Zandwijk, 2011; Siddeek et al., 2014). microRNAs are
protected from degradation by forming complexes with
circulating proteins or inclusion into protective shells such as
exosomes and apoptotic bodies (Gupta, Bang & Thum,
2010). Isolated RNA yields of microRNAs are low in
the serum and currently the most sensitive method of
detecting circulating microRNAs is reverse transcriptase
real-time PCR followed by normalization to synthetic C.
elegans or other endogenous circulating microRNAs (Gupta
et al., 2010). However expression levels of these endogenous
microRNAs are variable among patients with different risk
factors or after exposure to chemicals and drugs (Gupta
et al., 2010; Siddeek et al., 2014). Hence the best method to
normalize PCR data is arguable.
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A number of cardiac microRNAs, including miR-1/133a
and miR-208a, have altered serum levels in cardiovascular
disease such as AMI, heart failure and coronary artery disease
(Gupta et al., 2010). Blood samples collected from rat models
of AMI showed that levels of miR-1/133a and miR-208a
peaked at 3–12 h and then decreased over the next 12 h
with miR-208a being undetectable 24 h after onset; a similar
pattern is observed in human patients with AMI (Wang et al.,
2010a). These trends mimic cardiac biomarkers already in
clinical use and thus may have a diagnostic role in the future.
Decreased miR-133a levels in the blood can also serve as
a predictive marker of cardiac hypertrophy in patients on
haemodialysis (Wen et al., 2014).
Several microRNAs were found to have altered levels
in the serum of patients with tissue rejection following a
heart transplant: miR-10a, miR-31, miR-92a and miR-155;
these may serve as non-invasive biomarkers, removing the
need for tissue biopsies (Duong Van Huyen et al., 2014).
Similarly, miR-199a-5p, miR-27a and miR-29a can aid as
potential prognostic markers in patients with hypertrophic
cardiomyopathy to assess left ventricular hypertrophy and
fibrosis (miR-29a only) (Roncarati et al., 2014). Hypertrophic
cardiomyopathy is a heritable disease that may go undetected
for many years prior to sudden death and hence regular
monitoring of these potential biomarkers may assist in the
prevention of fatal events.
(2) Antisense therapy
Antisense therapy uses a gain-of-function or microRNA
replacement strategy. The gain of function approach is
more widely acceptable and uses synthetic complemen-
tary sequences to the microRNA, anti-microRNA oligonu-
cleotides, that disallow formation of the RNA-silencing
complex or induce degradation of the microRNA, thus per-
mitting the target mRNA to continue with its function (Bader,
Brown & Winkler, 2010). The other approach restores the
function of a microRNA by introducing a synthetic mimic,
plasmid DNA or cofactor/promoter stimulating agents that
can then suppress the function of an undesirable or overex-
pressed gene (Zhang, Wang & Gemeinhart, 2013a).
Synthesizing chemically modified complementary
sequences to the precursor or mature microRNA can treat a
disease resulting from suppression of mRNAs by microRNAs
(Weiler, Hunziker & Hall, 2006). The modifications are
meant to increase target specificity and include addition
of 2′-O-methyl, 2′z-O-methoxyethyl and 2′-O-modified
(locked nucleic acid modified oligonucleotides) groups to the
oligonucleotide (Weiler et al., 2006). A study demonstrated
the pharmacological characteristics of antagomirs through
injecting anti-miR-122 and anti-miR-16 into rats and then
analysing their properties in all the major organs. It was
found that inhibition of miR-122 was dose dependent
and that levels of the inhibitor were detectable until
23 days after injection (Kru¨tzfeldt et al., 2005). Additionally,
bioavailability of anatgomir-16 was abundant in all tissues
except for the brain, possibly due to selective permeability
of the blood–brain barrier (Kru¨tzfeldt et al., 2005). Lastly,
raised blood alanine aminotransferase (ALT) levels, which
are an indicator of hepatotoxicity, were undetectable after
treatment suggesting that the synthetic oligonucleotides are
potentially safe for therapeutic use (Kru¨tzfeldt et al., 2005).
Delivery of a microRNA mimic or inhibitor is also crucial
in gene therapy and can be broadly grouped as synthetic
and viral delivery systems, both having their own sets of
benefits and limitations. Synthetic delivery systems include
liposomes, polyethylenimine (PEI)-based, dendrimers,
poly(lactide-co-glycolide) (PLGA) particles and natural
polymers like chitosan, protamine and collagen (Zhang et al.,
2013a). These synthesized particles have certain advantages
over viral systems such as modifiable composition, easy
synthesis and a reduced immune response (Zhang et al.,
2013a).
The use of synthetic oligonucleotides as mainstream
tools for genetic therapy is inevitable with our continuing
understanding of the function and downstream effects of
microRNA-led regulation of cellular process and pathways.
VIII. CONCLUSIONS
(1) Aging of the heart is a continuous process with the
journey starting from the embryonic formation of the heart
tube until the eventual death of cardiac cells due to various
pathological insults. Physiological cardiac hypertrophy is
part of the normal growth process whereas pathological
cardiac hypertrophy is a compensatory response to increased
cardiac and circulatory stress that leads to expression of
inherent myocardial genes. However, it is now believed
that the compensatory response may also result from fewer
terminally differentiated cardiomyocytes after birth for which
the heart makes up by increasing cell size.
(2) The HHR is a unique model to study cardiac
hypertrophy because myocardial remodelling is due to
inherent activation of hypertrophic genes in the absence
of any external stimuli.
(3) MicroRNAs are recognized to provide another layer of
regulatory control on cellular processes. Several microRNAs
have previously been investigated in hypertrophic hearts,
which can be potentially used as diagnostic and therapeutic
tools.
(4) It is necessary to continue investigating the various
cellular pathways regulated by these microRNAs and others
to understand cardiac adaptation better in the quest of
finding that perfect microRNA or combination as the
ultimate tool/s for genetic therapy.
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